Using a new scan to measure liver scarring in NASH
Part of Digestive system clinical trials.
This study tests if a new imaging agent (68Ga-FAPI-46) can accurately measure liver scarring (fibrosis) in people with NASH, a type of fatty liver disease. It may offer a way to track liver damage without needing repeated biopsies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had a recent liver biopsy that shows you have or might have NASH (a type of fatty liver disease).
- You cannot have hepatitis B or C.
- You cannot have advanced liver cirrhosis with complications like belly fluid or yellowing of the skin.
- You must not have taken certain medications (like steroids or methotrexate) that can cause fatty liver.
- You must not have had more than 2 drinks a day (men) or 1 drink a day (women) in the last 5 years.
- You must be well enough to have a PET scan (a special imaging test).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This study tests a new injected drug (TQA2225/AP025) that may help reduce liver fat and inflammation in people with NASH (a type of fatty liver disease with scarring). It’s for adults who have had a recent liver biopsy and MRI confirming NASH and moderate liver fat.
This study is for people with NASH and moderate-to-advanced liver scarring (fibrosis). Researchers want to see if they can better measure how the scarring changes over time using a liver biopsy.
This study is creating better ways to measure if liver scarring from NASH (a type of fatty liver disease) has improved. It may help doctors know if treatments are working.
This study checks whether an MRI scan can measure liver health in people with suspected fatty liver disease that may have progressed to NASH. Everyone in the study is also scheduled for a standard liver biopsy, which is used to compare the scan results.
This trial studies how well a special imaging test (68Ga-FAPI PET/MRI) can detect and evaluate hepatocellular carcinoma (HCC), a type of liver cancer. It may help doctors confirm diagnosis and plan next steps by seeing how the cancer takes up the tracer.
Hear when a new Non-alcoholic Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.